Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.46 | N/A | +13.02% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.46 | N/A | +13.02% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains cautiously optimistic about the company's future, emphasizing the strength of their product pipeline. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted the strength of their pipeline.
They expressed confidence in future product launches.
No specific guidance was provided for the upcoming quarters.
Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which likely contributed to the stock's increase of nearly 4%. The management's focus on their product pipeline suggests they are confident about future growth, even without specific guidance. Investors may view this as a sign of stability in uncertain market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NETFLIX INC
Jan 26, 2009